For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | 54,515 | 36,957* | 60,635 | 49,762 |
| General and administrative | 15,509 | 9,370* | 10,799 | 10,936 |
| Total operating expenses | 70,024 | 46,326 | 71,434 | 60,698 |
| Operating loss | -70,024 | -46,326* | -71,434 | -60,698 |
| Interest expense | 2,269 | -604* | 3,198 | 2,037 |
| Other income, net | 3,208 | 6,124* | 4,053 | 6,779 |
| Loss before income tax | -69,085 | -39,598* | -70,579 | -55,956 |
| Income tax expense | 622 | 296* | 115 | 95 |
| Net loss | -69,707 | -39,894 | -70,694 | -56,051 |
| Of which net loss attributable to noncontrolling interests shareholders | - | - | - | -831 |
| Of which net loss attributable to controlling interests shareholders | -69,707 | -39,894 | -69,729 | -55,220 |
| Basic EPS | -0.98 | -0.598 | -1.1 | -0.87 |
| Diluted EPS | -0.98 | -0.598 | -1.1 | -0.87 |
| Basic Average Shares | 71,273,650 | 66,738,955 | 63,369,984 | 63,282,728 |
| Diluted Average Shares | 71,273,650 | 66,738,955 | 63,369,984 | 63,282,728 |
MoonLake Immunotherapeutics (MLTX)
MoonLake Immunotherapeutics (MLTX)